Prospective Cohort With Hemopathy in Languedoc-Roussillon | NCT02134574

Studies
Prospective Cohort With Hemopathy in Languedoc-Roussillon

NCT02134574

Sponsor

University Hospital, Montpellier

Status

Recruiting

Last Update Posted

Jun 22, 2026Actual

Enrollment

500Estimated

Phase

Not provided

Conditions

Hematologic Malignancy

Interventions

hematologic malignancy

Countries

France

Protocol Section

Identification Module Status Module Sponsor/Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms/Interventions Module Outcomes Module Eligibility Module Contacts/Locations Module References Module IPD Sharing Statement Module

Results Section

Participant Flow Module Baseline Characteristics Module Outcome Measures Module Adverse Events Module More Info Module

Annotation Section

Annotation Module

Document Section

Large Document Module

Derived Section

Miscellaneous Info Module Condition Browse Module Intervention Browse Module

Protocol Section

Identification Module

NCT ID

Results Section

No data available

No data is available for this block.

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Version Holder

Status Module

Record Verification Date

Jun 2026

Overall Recruitment Status or Expanded Access Status

Recruiting

Last Known Status

Not provided

Delayed Posting

Not provided

Why Stopped

Not provided

Expanded Access Info

Start Date

Feb 2014

Primary Completion Date

Jun 2033Estimated

Completion Date

Jun 2033Estimated

First Submitted Date

Apr 22, 2014

First Submission Date that Met QC Criteria

May 6, 2014

First Posted Date

May 9, 2014Estimated

Results Waived

Not provided

Results First Submitted Date

Not provided

Results First Submitted that Met QC Criteria

Not provided

Results First Posted Date

Not provided

Certification/Extension (aka Delayed Results) First Submitted Date

Not provided

Certification/Extension First Submitted that Passed QC Review

Not provided

Certification/Extension First Posted Date

Not provided

Last Update Submitted Date

Jun 17, 2026

Last Update Posted Date

Jun 22, 2026Actual

Oversight Module

Has Data Monitoring Committee (DMC)

Is FDA Regulated Drug

Not provided

Is FDA Regulated Device

Not provided

Is Unapproved Device

Not provided

Pediatric Postmarket Surveillance of a Device Product

Not provided

Product Exported from US

Not provided

FDAAA801 Violation

Not provided

Description Module

Brief Summary

Prospective Cohort Study of clinical and laboratory data of patients with hemopathy.

Detailed Description

Prospective Cohort Study of clinical and laboratory data of patients with hemopathy in LR.

Design Module

Study Type

Observational

Number of References to an Expanded Access Study

Not provided

Expanded Access Types

Not provided

Patient Registry

Target Follow-Up Duration

Not provided

Phases

Not provided

Interventional Study Design

Allocation

Not provided

Intervention Model

Biospecimen

Retention

Enrollment

500Estimated

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
hematologic malignancy		hematologic malignancy with a sampling of blood	Biological: hematologic malignancy

Interventions

Name	Type	Description	Arm Group Labels	Other Names
hematologic malignancy	Biological	hematologic malignancy with a sampling of blood	hematologic malignancy

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Survival with 2 years	Prospective Cohort Study of clinical and biological data Analysis Biological, clinical and questionnaire EORTC_QLQ-C30	2 years

Secondary Outcomes

Measure	Description	Time Frame
Survival with 5 years	Prospective Cohort Study of clinical and biological data Analysis Biological, clinical and questionnaire EORTC_QLQ-C30	5 years
Survival with 10 years	Prospective Cohort Study of clinical and biological data Analysis Biological, clinical and questionnaire EORTC_QLQ-C30

Other Outcomes

Not provided

Eligibility Module

Eligibility Criteria

Inclusion criteria:

Age over 18
Consultant or hospitalized patient for suspected malignant hemopathy and justifying further exploration or patient with a diagnosis of malignant hemopathy less than 6 months old at the time of signing the consent
Having signed an informed consent
Affiliated with a social security scheme

Exclusion criteria:

Minor or major protected
Patients who have received treatment for hematological pathology

Accepts Healthy Volunteers

Sex

All

Sex/Gender Based

Not provided

Sex/Gender Description

Not provided

Minimum Age

18 Years

Maximum Age

Not provided

Standard Ages

AdultOlder Adult

Study Population

patient for suspected haematological disease and justifying further exploration

Sampling Method

Probability Sample

Contacts/Locations Module

Central Contacts

Name	Role	Phone	Extension	Email
Valerie ROUILLE	Contact			v-rouille@chu-montpellier.fr

Overall Officials

Name	Affiliation	Role
GUILLAUME CARTRON	University Hospital, Montpellier	Principal Investigator

Locations

Facility	Status	City	State	ZIP	Country	Contacts
Hematology department - UHMontpellier Saint éloi	Recruiting	Montpellier			France

Condition Browse Module

MeSH Terms

ID	Term
D019337	Hematologic Neoplasms
D008223	Lymphoma
D007938	Leukemia
D009101	Multiple Myeloma
D006689	Hodgkin Disease

Ancestor Terms

ID	Term
D009371	Neoplasms by Site
D009369	Neoplasms
D006402	Hematologic Diseases
D006425	Hemic and Lymphatic Diseases

Browse Leaves

Not provided

Browse Branches

Not provided